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crinology reported that left ventricular hypertrophy (LVH) is absent in Hyp mice with elevated FGF-23. This finding is unexpected and controversial because excess FGF-23 concentrations are associated with LVH and linked to increased cardiovascular mortality in patients with chronic kidney disease and the general population (2) . Moreover, pharmacological administration of recombinant FGF-23 has established a causal link between FGF-23 and LVH in mice (3) . These findings also are inconsistent with other results showing that elevated FGF-23 levels in hypophosphatemic Hyp mice are associated with LVH (4-6). Their proposition that hyperphosphatemia is required for FGF-23's cardiovascular effects is inconsistent with the ability of recombinant FGF-23 administration to induce LVH in the absence of hyperphosphatemia (3). Moreover, their observation of increased expression of cardiac hypertrophy markers in C2C12 skeletal muscle cells exposed to sodium phosphate in vitro is of questionable translational relevance (1) . Conclusions regarding the role of FGF-23 in the pathogenesis of cardiovascular disease should be based on studies of high scientific rigor. The findings reported in Liu et al. (1) are not sufficient to discredit an independent role for FGF-23 or to establish an obligate requirement for phosphate in FGF-23dependent LVH.
Failure to observe LVH in Hyp mice in the study by Liu et al. (1) suggests the presence of confounding dietary, environmental, age-related, and/or genetic factors that prevented the identification of cardiovascular abnormalities. Recent studies have shown that alterations in the microbiome affect circulating FGF-23 levels (7) . In addition, FGF-23 levels in Hyp mice showed a significant reduction from ;5000 pg/mL to ;1200 pg/mL from 3 to 12 weeks of age (8) . The Hyp mice in the study by Liu et al. (1) were 30 weeks old, but LVH was observed in 6-week-old mice Hyp mice (4, 6) . The serum FGF-23 levels were not reported in the study by Liu et al. (1); however, the FGF-23 levels might have been below a threshold necessary to induce LVH.
A bone-renal-cardiac endocrine axis has been proposed to explain the cardiovascular effects of excess FGF-23 through activation of FGFR/a-Klotho binary complexes in kidney tubules. In this schema, the FGF-23 produced by bone regulates cardiovascular homeostasis by (i) stimulating the sodium-chloride channel in distal renal tubules leading to sodium retention, suppression of aldosterone, and elevation of blood pressure (6); (ii) suppressing angiotensin-converting enzyme 2, leading to activation of the renin-angiotensin system, a finding indirectly supported by exacerbation of angiotensin IIinduced LVH in rodents in the setting of excess FGF-23 (5); and/or (iii) decreasing ectodomain shedding of soluble Klotho (sKL) into the circulating from the kidney and loss of the cardioprotective effects of sKL, mediated by upregulation of the transient receptor potential cation channel subfamily C member 6 (TRPC6) in the myocardium. A "TRPC6" cardiac transcriptome signature characterizes FGF-23-induced LVH, and recombinant sKL administration lowers blood pressure and prevents LVH (4, 9) . Alternatively, the direct effects of FGF-23 to stimulate LVH by activating FGFR4 in the myocardium in the absence of a-Klotho have been proposed (10) . Thus, the available data indicate that FGF-23 alone has either indirect and/ or direct effects to induce LVH.
Interactions among FGF-23, Klotho, and hyperphosphatemia to cause adverse cardiovascular outcomes need further study. The clinical correlation between elevated FGF-23 and LVH has been most evident in hyperphosphatemic patients with chronic kidney disease and low sKL levels. Moreover, phosphate loading has been shown to elevate FGF-23 (3) and to suppress a-Klotho. Further investigations of the interactions among excess FGF-23, sKL deficiency, and hyperphosphatemia on the cardiovascular system are needed.
